Skip to content

Efficacy and Safety of Baricitinib in refractory Non-infectious Uveitis

Efficacy and Safety of Baricitinib in refractory Non-infectious Uveitis

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100048030
Enrollment
Unknown
Registered
2021-06-28
Start date
2021-07-01
Completion date
Unknown
Last updated
2022-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-infectious Uveitis

Interventions

Case series:Baricitinib

Sponsors

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 60 years old; 2. According to the diagnostic criteria of refractory NIU, patirnts should meet one of the following items 2, 3 and 4 on the basis of Item 1: (1) Non infective intermediate uveitis, posterior uveitis or panuveitis; (2) While receiving at least one common immunosuppressant, it is difficult to reduce glucocorticoids; (3) The patients were intolerant to glucocorticoids or immunosuppressants due to side effects; (4) The newly diagnosed patients with VKH or Behcet's disease-related uveitis need long-term immunosuppressive therapy; 3. Active uveitis disease must be present at day 1/baseline, and more than one of the following conditions is required: (1) Active, inflammatory, chorioretinal and/or inflammatory retinopathy; (2) Anterior chamber cells >=2 + (evaluated according to SUN criteria); (3) Inflammatory vitreous opacity >=2 + (evaluated according to SUN criteria).

Exclusion criteria

Exclusion criteria: 1. Patients had no willingness to participate in the clinical trial; 2. Dignosis of infectious uveitis, such as viral uveitis, tuberculous uveitis, fungal infection and Toxoplasma gondii infection, or can not be excluded; 3. Complicated with severe glaucoma and complicated cataract; 4. Systemic screening combined with tuberculosis and hepatitis B, and without standardized anti-tuberculosis and anti-hepatitis B virus treatment; 5. Combined with uncontrolled systemic diseases such as hypertension, diabetes; 6. Liver and kidney dysfunction; 7. Pregnant women and lactation; 8. Previous severe cardiovascular and cerebrovascular diseases.

Design outcomes

Primary

MeasureTime frame
Vision;

Countries

China

Contacts

Public ContactSun Xufang

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

sunxufang2016@163.com+86 18627770651

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 19, 2026